Latest Romidepsin Stories
Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer.
Gloucester Pharmaceuticals today announced that positive data from a Phase 2 trial of romidepsin conducted by the U.S. National Cancer Institute (NCI) were presented at the 13th Congress of the European Hematology Association in Copenhagen, Denmark.